LAI
VRTX icon

Legal Advantage Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Legal Advantage Investments’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,848
Closed -$823K – 98
2025
Q2 		$823K Hold
1,848
– – 0.38% 57
2025
Q1 		$896K Buy
1,848
+18
+1% +$8.39K 0.48% 52
2024
Q4 		$737K Hold
1,830
– – 0.39% 60
2024
Q3 		$851K Hold
1,830
– – 0.47% 53
2024
Q2 		$858K Hold
1,830
– – 0.49% 51
2024
Q1 		$765K Buy
1,830
+505
+38% +$213K 0.43% 52
2023
Q4 		$539K Buy
+1,325
New +$489K 0.32% 66

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Legal Advantage Investments's VRTX Position: Q3 2025 in Review

Legal Advantage Investments sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 1,848 shares — an estimated $823K sold.

Legal Advantage Investments first reported a position in VRTX in Q4 2023 and held it in 7 quarters. The position peaked at $896K in Q1 2025. 1,520 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • Legal Advantage Investments reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Legal Advantage Investments sold 1,848 Vertex Pharmaceuticals shares in Q3 2025, an estimated $823K.
  • Legal Advantage Investments first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 7 quarters.
  • Legal Advantage Investments's Vertex Pharmaceuticals position peaked at $896K in Q1 2025.
  • 1,520 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Legal Advantage Investments's 13F filing for Q3 2025, filed 20 Oct 2025.